BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18245537)

  • 1. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
    Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
    Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
    Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
    Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
    Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
    Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
    Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
    Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
    Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.
    Wang Z; Zhang Y; Mandal A; Zhang J; Giles FJ; Herr JC; Lim SH
    Clin Cancer Res; 2004 Oct; 10(19):6544-50. PubMed ID: 15475442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
    Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
    Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.
    Desmetz C; Bibeau F; Boissière F; Bellet V; Rouanet P; Maudelonde T; Mangé A; Solassol J
    J Proteome Res; 2008 Sep; 7(9):3830-7. PubMed ID: 18683965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemiluminescent optical fiber immunosensor for detection of autoantibodies to ovarian and breast cancer-associated antigens.
    Salama O; Herrmann S; Tziknovsky A; Piura B; Meirovich M; Trakht I; Reed B; Lobel LI; Marks RS
    Biosens Bioelectron; 2007 Feb; 22(7):1508-16. PubMed ID: 16904309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens.
    Ehrlich JR; Tang L; Caiazzo RJ; Cramer DW; Ng SK; Ng SW; Liu BC
    Methods Mol Biol; 2008; 441():175-92. PubMed ID: 18370319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
    Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
    Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.
    Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM
    Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
    Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
    Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.